Investor Profile: Aisling Capital — Thesis, Cheque Size & How to Apply

Aisling Capital is a New York-based, life sciences-dedicated investment firm, and Aisling Capital funding is aimed squarely at late-stage companies turning breakthrough science into approved medicines. The firm describes itself as a late-stage life sciences investment partnership that uses decades of capital markets and clinical experience to develop and bring to market therapeutics that improve and save lives.

Investment thesis

Aisling invests in companies developing pharmaceutical and medical products, as well as businesses that provide drug development, manufacturing and other important services to the healthcare industry. It invests in both private and public companies, using a wide variety of investment structures, and its team's combination of clinical, operational, transactional and capital markets experience is central to how it picks and supports investments.

Sectors and stages

Aisling is a late-stage investor. Its therapeutic interests named at the close of its fourth fund included oncology, aesthetic dermatology and women's health, within a broader biopharmaceutical remit. It backs companies that are typically in clinical development or approaching commercialisation, rather than seed-stage science projects, and it is registered as an investment adviser with the U.S. Securities and Exchange Commission.

Fund size and cheque size

Aisling closed its fourth fund, Aisling Capital IV, at $280 million in 2017, and an earlier fund close announced by the firm totalled $650 million. Its current total assets under management are not publicly disclosed on its website, and its typical cheque size is not publicly disclosed; founders should therefore focus on stage fit, late-stage clinical or commercial companies, rather than a published cheque range.

Notable portfolio

Companies featured in Aisling's own news flow include BridgeBio Pharma, which has submitted new drug applications for encaleret and BBP-418; Compass Pathways, the mental health biotechnology company advancing COMP360 for treatment-resistant depression; Monte Rosa Therapeutics, developer of molecular glue degrader medicines; Allotera Therapeutics (formerly Wugen), developer of off-the-shelf CAR-T therapies for T-cell cancers; and Veradermics, a dermatologist-founded company focused on aesthetic and dermatological conditions. Earlier portfolio names tracked by third parties include Cidara Therapeutics, T2 Biosystems and Seragon Pharmaceuticals.

Partners and team

The firm is led by Managing Partners Steve Elms and Andrew Schiff, M.D. Aisling is headquartered in New York at 489 Fifth Avenue, and its partners bring capital markets and clinical experience to every investment.

Programmes and perks

No public accelerator, credits or perks programme run by Aisling Capital was found in the sources we read. Its support model is direct investment plus strategic guidance and operational assistance to portfolio companies, drawing on its healthcare expertise, rather than a structured programme with open applications.

How to apply for funding

Aisling Capital publishes no open application form or funding portal on its website. Founders of late-stage life sciences companies should approach the firm directly through the contact details on aislingcapital.com, ideally with a warm introduction from an existing investor or adviser, a clear clinical data package, and a credible path to commercialisation. Cold outreach should be concise and specific about stage, indication and financing need.